Composition and method for modulating BAR/FXR receptor activity
AssigneeAllergan Sales, Inc.
InventorsBarry M. Forman, Richard L. Beard, Isabelle Dussault, Roshantha A. Chandraratna
Life of this patent
Estimating the term…
Abstract
Methods for modulating the activity of the mammalian BAR/FXR receptor. The methods include methods of treating a hypocholesterolemic mammal comprising contacting the mammal with synthetic compounds able to modulate an activity characteristic of the BAR/FXR receptor. Other methods include a method of treating colon cancer in a mammal comprising administering a compound having a BAR/FXR antagonistic activity.
Claims10
A method of treating a pathological condition in a mammal characterized by hypocholesterolemia comprising the step of providing to said mammal a pharmaceutically acceptable composition comprising a synthetic BARIFXR ligand selected from the group consisting of AGN 29 and AGN 31.
A method of treating a pathological condition in a mammal characterized by pathological expression of IBABP, comprising the step of providing to said mammal a pharmaceutically acceptable composition comprising AGN 34, thereby treating said condition.
A method of treating colon cancer in a mammal without increasing the expression of Cyp7A comprising the step of providing to said mammal a pharmaceutically acceptable composition comprising AGN 34.
A method of inhibiting the bile-acid mediated growth of cancer cells in a mammalian cell comprising administering a composition comprising a pharmaceutically effective amount of AGN 34.
Dependencies are inferred from the claim text.